MA-104 Cells
USD$550.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | The MA-104 cell line is derived from rhesus monkey kidney epithelial cells and is widely used in virology and vaccine production research. These cells exhibit a typical epithelial morphology, adhering tightly to the substrate and forming a monolayer. Due to their origin, MA-104 cells are particularly permissive to the replication of various viruses, including rotaviruses, polioviruses, and reoviruses, making them an essential tool in virological studies, especially in the propagation and isolation of these pathogens. Their high susceptibility to viral infection allows for efficient viral growth, which is crucial for vaccine development and testing. In addition to their role in virology, MA-104 cells are also employed in studies focusing on cell biology and physiology, particularly those investigating kidney function and epithelial cell behavior. These cells have been instrumental in understanding the mechanisms of viral entry, replication, and the host-cell response to infection. Researchers also utilize MA-104 cells to study protein expression and post-translational modifications due to their ability to support high levels of protein production. |
|---|---|
| Organism | Chlorocebus pygerythrus (Vervet monkey) |
| Tissue | Kidney |
| Synonyms | Ma-104, MA 104, MA104, Microbiological Associates-104 |
Characteristics
| Age | Fetus |
|---|---|
| Morphology | Epithelial |
| Growth properties | Adherent |
Regulatory Data
| Citation | MA-104 (Cytion catalog number 305007) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9534 |
| CellosaurusAccession | CVCL_3845 |
Biomolecular Data
Handling
| Culture Medium | EMEM (MEM Eagle), w: 2 mM L-Glutamine, w: 2.2 g/L NaHCO3, w: EBSS (Cytion article number 820100a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS and 1% NEAA |
| Dissociation Reagent | Accutase |
| Subculturing | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
| Fluid renewal | 2 to 3 times per week |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 305007-141222 | Certificate of Analysis | 22. Jan. 2026 | 305007 |